High-Dose Oral and Intravenous Rifampicin for the Treatment of Tuberculous Meningitis in Predominantly Human Immunodeficiency Virus (HIV)-Positive Ugandan Adults: A Phase II Open-Label Randomized Controlled Trial | Zendy

Fiona V Cresswell | Zendy; David B. Meya | Zendy; Enock Kagimu | Zendy; Daniel Grint | Zendy; Lindsey te Brake | Zendy; John Kasibante | Zendy; Emily Martyn | Zendy; Morris K Rutakingirwa | Zendy; Carson Quinn | Zendy; Michael Okirwoth | Zendy; Lillian Tugume | Zendy; Kenneth Ssembambulidde | Zendy; Abdu Musubire | Zendy; Ananta Bangdiwala | Zendy; Allan Buzibye | Zendy; Conrad Muzoora | Zendy; Elin M. Svensson | Zendy; Rob E. Aarnoutse | Zendy; David R. Boulware | Zendy; Alison M. Elliott | Zendy

Open Access

High-Dose Oral and Intravenous Rifampicin for the Treatment of Tuberculous Meningitis in Predominantly Human Immunodeficiency Virus (HIV)-Positive Ugandan Adults: A Phase II Open-Label Randomized Controlled Trial

Author(s) -

Fiona V Cresswell,

David B. Meya,

Enock Kagimu,

Daniel Grint,

Lindsey te Brake,

John Kasibante,

Emily Martyn,

Morris K Rutakingirwa,

Carson Quinn,

Michael Okirwoth,

Lillian Tugume,

Kenneth Ssembambulidde,

Abdu Musubire,

Ananta Bangdiwala,

Allan Buzibye,

Conrad Muzoora,

Elin M. Svensson,

Rob E. Aarnoutse,

David R. Boulware,

Alison M. Elliott

Publication year - 2021

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciab162

Subject(s) - medicine , rifampicin , interquartile range , dosing , cmax , pharmacokinetics , adverse effect , gastroenterology , confidence interval , pharmacology , tuberculosis , pathology

High-dose rifampicin may improve outcomes of tuberculous meningitis (TBM). Little safety or pharmacokinetic (PK) data exist on high-dose rifampicin in human immunodeficiency virus (HIV) coinfection, and no cerebrospinal fluid (CSF) PK data exist from Africa. We hypothesized that high-dose rifampicin would increase serum and CSF concentrations without excess toxicity.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research